Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma

References

• Lai J L, Zandecki M, Mary J Y, Bernardi F, Izydorczyk V, Flactif M, et al. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 1995; 85: 2490–2497
   PubMed Web of Science ®Google Scholar
• Taniwaki M, Nishida K, Ueda Y, Takashima T. Non-random chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia. Leuk Lymphoma 1996; 21: 25–30
   PubMed Web of Science ®Google Scholar
• Sawyer J R, Waldron J A, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995; 82: 41–49
   PubMed Web of Science ®Google Scholar
• Bergsagel P L, Chesi M, Nardini E, Brents L A, Kirby S L, Kuehl W M. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 1996; 93: 13931–13936
   PubMed Web of Science ®Google Scholar
• Chesi M, Nardini E, Brents L A, Schrock E, Ried T, Kuehl W M, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16: 260–264
   PubMed Web of Science ®Google Scholar
• Passos-Bueno M R, Wilcox W R, Jabs E W, Sertie A L, Alonso L G, Kitoh H. Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat 1999; 14: 115–125
   PubMed Web of Science ®Google Scholar
• Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R, et al. A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 1997; 90: 4062–4070
   PubMed Web of Science ®Google Scholar
• Fonseca R, Blood E, Rue M, Harrington D, Oken M M, Kyle R A, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569–4575
   PubMed Web of Science ®Google Scholar
• Fenton J A, Pratt G, Rawstron A C, Sibley K, Rothwell D, Yates Z, et al. Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism. Oncogene 2003; 22: 1103–1113
   PubMed Web of Science ®Google Scholar
• Stec I, Wright T J, van Ommen G J, de Boer P A, van Haeringen A, Moorman A F, et al. WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf – Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum Mol Genet 1998; 7: 1071–1082
   PubMed Web of Science ®Google Scholar
• Chesi M, Nardini E, Lim R S, Smith K D, Kuehl W M, Bergsagel P L. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998; 92: 3025–3034
   PubMed Web of Science ®Google Scholar
• Still I H, Vince P, Cowell J K. The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines. Genomics 1999; 58: 165–170
   PubMed Web of Science ®Google Scholar
• Keats J J, Reiman T, Maxwell C A, Taylor B J, Larratt L M, Mant M J, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003; 101: 1520–1529
   PubMed Web of Science ®Google Scholar
• Chesi M, Bergsagel P L, Shonukan O O, Martelli M L, Brents L A, Chen T, et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998; 91: 4457–4463
   PubMed Web of Science ®Google Scholar
• Boersma-Vreugdenhil G R, Kuipers J, Van Stralen E, Peeters T, Michaux L, Hagemeijer A, et al. The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: a molecular and genetic analysis of the chromosomal breakpoint. Br J Haematol 2004; 126: 355–363
   PubMed Web of Science ®Google Scholar
• Smadja N V, Leroux D, Soulier J, Dumont S, Arnould C, Taviaux S, et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 2003; 38: 234–239
   PubMed Web of Science ®Google Scholar
• Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J, Jr. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 2003; 101: 2374–2376
   PubMed Web of Science ®Google Scholar
• Chang H, Stewart A K, Qi X Y, Li Z H, Yi Q L, Trudel S. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 2005; 106: 353–355
   PubMed Web of Science ®Google Scholar
• Jaksic W, Trudel S, Chang H, Trieu Y, Qi X, Mikhael J, et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005; 23: 7069–7073
   PubMed Web of Science ®Google Scholar
• Nakazawa N, Nishida K, Tamura A, Kobayashi M, Iwai T, Horiike S, et al. Interphase detection of t(4;14)(p16.3;q32.3) by in situ hybridization and FGFR3 overexpression in plasma cell malignancies. Cancer Genet Cytogenet 2000; 117: 89–96
   PubMed Web of Science ®Google Scholar
• Stewart J P, Thompson A, Santra M, Barlogie B, Lappin T R, Shaughnessy J, Jr. Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma. Br J Haematol 2004; 126: 72–76
   PubMed Web of Science ®Google Scholar
• Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli M C, Colombo G, et al. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res 2000; 60: 4058–4061
   PubMed Web of Science ®Google Scholar
• Soverini S, Terragna C, Testoni N, Ruggeri D, Tosi P, Zamagni E, et al. Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. Haematologica 2002; 87: 1036–1040
   PubMed Web of Science ®Google Scholar
• Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002; 99: 1745–1757
   PubMed Web of Science ®Google Scholar
• Munshi N C, Hideshima T, Carrasco D, Shammas M, Auclair D, Davies F, et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 2004; 103: 1799–1806
   PubMed Web of Science ®Google Scholar
• Fabris S, Agnelli L, Mattioli M, Baldini L, Ronchetti D, Morabito F, et al. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. Genes Chromosomes Cancer 2005; 42: 117–127
   PubMed Web of Science ®Google Scholar
• Dring A M, Davies F E, Fenton J A, Roddam P L, Scott K, Gonzalez D, et al. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res 2004; 10: 5692–5701
   PubMed Web of Science ®Google Scholar
• Keats J J, Maxwell C A, Taylor B J, Hendzel M J, Chesi M, Bergsagel P L, et al. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32) positive multiple myeloma patients. Blood 2005; 105: 4060–4069
   PubMed Web of Science ®Google Scholar
• Pilarski L M, Kaigala G V, VanDjiken J, Atrazhev A, Taylor B J, Belch A R, et al. Microfluidic devices for molecular monitoring of clonotypic IgH VDJ signatures and the t(4;14) translocation in mulitiple myeloma. Blood 2005; 106: A1536
   Google Scholar
• Pilarski L M, Lauzon J, Strachan E, Adamia S, Atrazhev A, Belch A R, et al. Sensitive detection using microfluidics technology of single cell PCR products from high and low abundance IgH VDJ templates in multiple myeloma. J Immunol Meth 2005; 305: 94–105
   PubMed Web of Science ®Google Scholar
• Debes-Marun C S, Belch A R, Pilarski L M. Circulating B lymphocytes from patients with multiple myeloma harbour t(4;14) translocations and chromosome 13 deletions. Blood 2005; 106: A500
   Google Scholar
• Avet-Loiseau H, Brigaudeau C, Morineau N, Talmant P, Lai J L, Daviet A, et al. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer 1999; 24: 9–15
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Facon T, Daviet A, Godon C, Rapp M J, Harousseau J L, et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res 1999; 59: 4546–4550
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp M J, Harousseau J L, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002; 99: 2185–2191
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Gerson F, Magrangeas F, Minvielle S, Harousseau J L, Bataille R. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001; 98: 3082–3086
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Li J Y, Facon T, Brigaudeau C, Morineau N, Maloisel F, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998; 58: 5640–5645
   PubMed Web of Science ®Google Scholar
• Chang H, Li D, Zhuang L, Nie E, Bouman D, Stewart A K, et al. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis. Leuk Lymphoma 2004; 45: 965–969
   PubMed Web of Science ®Google Scholar
• Chang H, Sloan S, Li D, Patterson B. Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization. Cancer Genet Cytogenet 2005; 156: 150–153
   PubMed Web of Science ®Google Scholar
• Chang H, Sloan S, Li D, Zhuang L, Yi O L, Chen C I, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004; 125: 64–68
   PubMed Web of Science ®Google Scholar
• Finelli P, Fabris S, Zagano S, Baldini L, Intini D, Nobili L, et al. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization. Blood 1999; 94: 724–732
   PubMed Web of Science ®Google Scholar
• Fonseca R, Oken M M, Greipp P R. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood 2001; 98: 1271–1272
   PubMed Web of Science ®Google Scholar
• Garand R, Avet-Loiseau H, Accard F, Moreau P, Harousseau J L, Bataille R. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003; 17: 2032–2035
   PubMed Web of Science ®Google Scholar
• Gertz M A, Lacy M Q, Dispenzieri A, Greipp P R, Litzow M R, Henderson K J, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837–2840
   PubMed Web of Science ®Google Scholar
• Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau J L, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100: 1579–1583
   PubMed Web of Science ®Google Scholar
• Sibley K, Fenton J A, Dring A M, Ashcroft A J, Rawstron A C, Morgan G J. A molecular study of the t(4;14) in multiple myeloma. Br J Haematol 2002; 118: 514–520
   PubMed Web of Science ®Google Scholar
• Fonseca R, Bailey R J, Ahmann G J, Rajkumar S V, Hoyer J D, Lust J A, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100: 1417–1424
   PubMed Web of Science ®Google Scholar
• Van Wier S A, Ahmann G J, Henderson K J, Greipp P R, Rajkumar S V, Larson D M, et al. The t(4;14) is present in patients with early stage plasma cell proliferative disorders including MGUS and smoldering multiple myeloma (SMM). ASH Annual Meeting Abstracts 2005; 106: 1545
   Google Scholar
• Kaufmann H, Ackermann J, Baldia C, Nosslinger T, Wieser R, Seidl S, et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 2004; 18: 1879–1882
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Hudlebusch H R, Knudsen L M, Johnsen H E. FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance. Br J Haematol 2002; 117: 626–628
   PubMed Web of Science ®Google Scholar
• Oken M M, Leong T, Lenhard R E, Jr, Greipp P R, Kay N E, Van Ness B, et al. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer 1999; 86: 957–968
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Harousseau J L, et al. A comprehenseive analysis of cytogenetic abnomalities in myeloma: results of the FISH analysis of 1000 patients enrolled in the IFM99 trials. Blood 2005; 106: A622
   Google Scholar
• Affer M, Robbiani D F, Chesi M, Bergsagel P L. Ectopic fibroblast growth factor receptor 3 (FGFR3) expression mediated by isotype switch recombination. Blood 2004; 104: 25A
   Google Scholar
• Chesi M, Brents L A, Ely S A, Bais C, Robbiani D F, Mesri E A, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001; 97: 729–736
   PubMed Web of Science ®Google Scholar
• Li Z, Zhu Y X, Plowright E E, Bergsagel P L, Chesi M, Patterson B, et al. The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood 2001; 97: 2413–2419
   PubMed Web of Science ®Google Scholar
• Plowright E E, Li Z, Bergsagel P L, Chesi M, Barber D L, Branch D R, et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 2000; 95: 992–998
   PubMed Web of Science ®Google Scholar
• Ronchetti D, Greco A, Compasso S, Colombo G, Dell'Era P, Otsuki T, et al. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 2001; 20: 3553–3562
   PubMed Web of Science ®Google Scholar
• Webster M K, Donoghue D J. Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain. Mol Cell Biol 1997; 17: 5739–5747
   PubMed Web of Science ®Google Scholar
• Fracchiolla N S, Luminari S, Baldini L, Lombardi L, Maiolo A T, Neri A. FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma. Blood 1998; 92: 2987–2989
   PubMed Web of Science ®Google Scholar
• Intini D, Baldini L, Fabris S, Lombardi L, Ciceri G, Maiolo A T, et al. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br J Haematol 2001; 114: 362–364
   PubMed Web of Science ®Google Scholar
• Intini D, Baldini L, Lombardi L, Neri A. A novel mutation involving the carboxy terminal region of the FGFR3 gene in a multiple myeloma patient with t(4;14). Leukemia 2002; 16: 1201–1202
   PubMed Web of Science ®Google Scholar
• Onwuazor O N, Wen X Y, Wang D Y, Zhuang L, Masih-Khan E, Claudio J, et al. Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood 2003; 102: 772–773
   PubMed Web of Science ®Google Scholar
• Trudel S, Li Z H, Wei E, Wiesmann M, Chang H, Chen C, et al. CHIR-258, a novel, multi-targeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005; 105: 2941–2948
   PubMed Web of Science ®Google Scholar
• Trudel S, Ely S, Farooqi Y, Affer M, Robbiani D F, Chesi M, et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 2004; 103: 3521–3528
   PubMed Web of Science ®Google Scholar
• Trudel S, Stewart A K, Rom E, Wei E, Li Z H, Kotzer S, et al. The inhibitory anti-FGFR3 antibody, PRO-001 is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006; 107: 4039–4046
   PubMed Web of Science ®Google Scholar
• Grand E K, Chase A J, Heath C, Rahemtulla A, Cross N C. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 2004; 18: 962–966
   PubMed Web of Science ®Google Scholar
• Paterson J L, Li Z, Wen X Y, Masih-Khan E, Chang H, Pollett J B, et al. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br J Haematol 2004; 124: 595–603
   PubMed Web of Science ®Google Scholar
• Chen J, Lee B H, Williams I R, Kutok J L, Mitsiades C S, Duclos N, et al. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 2005; 24: 8259–8267
   PubMed Web of Science ®Google Scholar
• Choi H H, Jong H S, Park J H, Choi S, Lee J W, Kim T Y, et al. A novel ginseng saponin metabolite induces apoptosis and down-regulates fibroblast growth factor receptor 3 in myeloma cells. Int J Oncol 2003; 23: 1087–1093
   PubMed Web of Science ®Google Scholar
• Zhu L, Somlo G, Zhou B, Shao J, Bedell V, Solvak M L, et al. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma. Mol Cancer Ther 2005; 4: 787–798
   PubMed Web of Science ®Google Scholar
• Qian S, Somlo G, Zhou B, Zhu L, Mi S, Mo X, et al. Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor. Oligonucleotides 2005; 15: 1–11
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Theilgaard-Monch K, Hudlebusch H R, Lodahl M, Johnsen H E, Dahl I M. Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities. Br J Haematol 2003; 123: 253–262
   PubMed Web of Science ®Google Scholar
• Todoerti K, Ronchetti D, Agnelli L, Castellani S, Marelli S, Deliliers G L, et al. Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma. Br J Haematol 2005; 131: 214–218
   PubMed Web of Science ®Google Scholar
• Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev 2002; 12: 198–209
   PubMed Web of Science ®Google Scholar
• Rayasam G V, Wendling O, Angrand P O, Mark M, Niederreither K, Song L, et al. NSD1 is essential for early post-implantation development and has a catalytically active SET domain. EMBO J 2003; 22: 3153–3163
   PubMed Web of Science ®Google Scholar
• Strahl B D, Grant P A, Briggs S D, Sun Z W, Bone J R, Caldwell J A, et al. Set2 is a nucleosomal histone H3-selective methyltransferase that mediates transcriptional repression. Mol Cell Biol 2002; 22: 1298–1306
   PubMed Web of Science ®Google Scholar
• Garlisi C G, Uss A S, Xiao H, Tian F, Sheridan K E, Wang L, et al. A unique mRNA initiated within a middle intron of WHSC1/MMSET encodes a DNA binding protein that suppresses human IL-5 transcription. Am J Respir Cell Mol Biol 2001; 24: 90–98
   PubMed Web of Science ®Google Scholar
• Hudlebusch H R, Theilgaard-Monch K, Lodahl M, Johnsen H E, Rasmussen T. Identification of ID-1 as a potential target gene of MMSET in multiple myeloma. Br J Haematol 2005; 130: 700–708
   PubMed Web of Science ®Google Scholar
• Mattioli M, Agnelli L, Fabris S, Baldini L, Morabito F, Bicciato S, et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 2005; 24: 2461–2473
   PubMed Web of Science ®Google Scholar
• Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000; 95: 1925–1930
   PubMed Web of Science ®Google Scholar
• Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 2000; 96: 1505–1511
   PubMed Web of Science ®Google Scholar
• Intini D, Fabris S, Storlazzi T, Otsuki T, Ciceri G, Verdelli D, et al. Identification of a novel IGH-MMSET fusion transcript in a human myeloma cell line with the t(4;14)(p16.3;q32) chromosomal translocation. Br J Haematol 2004; 126: 437–439
   PubMed Web of Science ®Google Scholar
• Tajima E, Uranishi M, Iida S, Komatsu H, Nitta M, Ueda R. Global real-time quantification/reverse transcription-polymerase chain reaction for detecting proto-oncogenes associated with 14q32 chromosomal translocation in multiple myeloma. Haematologica 2005; 90: 559–562
   PubMed Web of Science ®Google Scholar
• Chang H, Stewart A K, Qi X Y, Li Z H, Yi Q L, Trudel S. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 2005; 106: 353–355
   PubMed Web of Science ®Google Scholar